← Back to Search

Procedure

Echocardiography for Anesthesia Effects on Heart Function

N/A
Recruiting
Led By Anahita Dabo-Trubelja, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 20-mins after anesthesia induction.
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how general anesthesia affects heart function and blood flow in people who experience low blood pressure during surgery.

Who is the study for?
This trial is for adults over 18 who need general anesthesia for surgery, with at least a 20-minute prep time before incision and normal blood pressure. It's not for those in emergency surgery, on anti-hypertensive or beta-blocker medications, or with a history of heart disease.
What is being tested?
The study uses echocardiography to observe how general anesthesia affects heart function and blood flow during surgery, especially when patients have low blood pressure after receiving anesthesia.
What are the potential side effects?
Since the intervention being studied is an observational technique (echocardiography), there are no direct side effects from it. However, risks may be associated with the underlying surgical procedure and use of anesthesia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 20-mins after anesthesia induction.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 20-mins after anesthesia induction. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The proportion of patients with post-induction hypotension (PIH)

Side effects data

From 2024 Phase 3 trial • 218 Patients • NCT00557193
70%
Alanine aminotransferase increased
58%
Mucositis oral
57%
Aspartate aminotransferase increased
57%
Febrile neutropenia
53%
Infections and infestations - Other, specify
48%
Neutrophil count decreased
33%
Hypokalemia
25%
Diarrhea
23%
White blood cell decreased
22%
Catheter related infection
22%
Anorexia
15%
Fever
15%
Platelet count decreased
13%
Dehydration
12%
Upper respiratory infection
12%
Skin infection
12%
Urinary tract infection
8%
Lung infection
8%
Skin ulceration
8%
Hypocalcemia
8%
Hyponatremia
7%
Alkaline phosphatase increased
7%
Anemia
7%
Weight loss
7%
Hyperglycemia
7%
Hypoglycemia
7%
Hypoxia
5%
Bronchial infection
5%
Enterocolitis infectious
5%
GGT increased
5%
Hypoalbuminemia
5%
Soft tissue infection
5%
Lymphocyte count decreased
5%
Skin and subcutaneous tissue disorders - Other, specify
3%
Sepsis
3%
Vomiting
3%
Pain
3%
Hypophosphatemia
3%
Pain of skin
3%
Oral pain
3%
Anaphylaxis
3%
Penile infection
3%
Erythema multiforme
2%
Blood and lymphatic system disorders - Other, specify
2%
Cardiac disorders - Other, specify
2%
Sinus tachycardia
2%
Irritability
2%
Scrotal infection
2%
Small intestine infection
2%
Fracture
2%
Wound complication
2%
Hyperkalemia
2%
Hypertriglyceridemia
2%
Generalized muscle weakness
2%
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
2%
Penile pain
2%
Pharyngeal mucositis
2%
Pleural effusion
2%
Stridor
2%
Dry skin
2%
Surgical and medical procedures - Other, specify
2%
Hypotension
2%
Acute kidney injury
2%
Anal mucositis
2%
Esophagitis
2%
Gastritis
2%
Nausea
2%
Bladder infection
2%
Wound infection
2%
Investigations - Other, specify
2%
Peripheral motor neuropathy
2%
Peripheral sensory neuropathy
2%
Epistaxis
2%
Pneumonitis
2%
Pulmonary edema
2%
Respiratory failure
2%
Hypertension
2%
Enterocolitis
2%
Acidosis
2%
Renal and urinary disorders - Other, specify
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A (Standard Risk MLL-G)
Arm B (IR/HR MLL-R Chemotherapy)
Arm C (Efficacy/ Dose Level 2)
Induction (All Patients)
Post Induction (Follow-up Only)
Arm C (Safety/ Dose Level 1)
Arm C (Safety/ Dose Level 2)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EchocardiographyExperimental Treatment1 Intervention
Patients participating in this study will undergo routine anesthetic and perioperative care with the addition of an echocardiography and Clearsight BP measurement.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Echocardiography
2013
Completed Phase 4
~11580

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
General anesthesia involves the use of inhalational agents (such as sevoflurane) and intravenous agents (such as propofol) that depress the central nervous system, leading to loss of consciousness and sensation. These agents cause vasodilation and myocardial depression, resulting in decreased systemic vascular resistance and cardiac output, which can lead to hypotension. This understanding is crucial for anesthesia patients because managing blood pressure is essential to ensure adequate organ perfusion and prevent complications during surgery.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,977 Previous Clinical Trials
599,477 Total Patients Enrolled
Anahita Dabo-Trubelja, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

Echocardiography (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05954832 — N/A
Anesthesia Research Study Groups: Echocardiography
Anesthesia Clinical Trial 2023: Echocardiography Highlights & Side Effects. Trial Name: NCT05954832 — N/A
Echocardiography (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05954832 — N/A
~160 spots leftby Jul 2027